Women who use the Ortho Evra birth control patch are at risk to suffer from life-threatening blood clots and strokes.
Our law firm is representing women across America with Ortho Evra injuries.
Ortho Evra is a trademark of Ortho-McNeil Pharma-
ceuticals
Inc. and is used for product identification purposes only.
Ortho Evra Side Effects
Timeline
The following is a summary
of key events relating to the Ortho Evra birth
control patch. To contact an attorney at Lieff
Cabraser to review your case without charge
or obligation please click
here, or feel free to telephone us toll-free
at 1-800-541-7358 and ask to speak with partner
Heather Foster.
• November 20, 2001:
FDA Approves Ortho Evra
The Food and Drug Administration approves Ortho Evra, a 1-inch square patch that slowly releases estrogen and progesterone when applied to the body.
• April 30, 2002:
Ortho Evra Birth Control Patch Introduced to Market
Ortho Evra, developed by the Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and marketed by Ortho-McNeil Pharmaceutical, Inc., is introduced as the first birth control patch approved by the U.S. Food and Drug Administration.
In death or serious injury cases, we will visit you where you live, at no cost, to discuss your legal rights and answer your questions.
We have retained leading, national medical experts to assist our clients with their Ortho Evra claims.
• July 16, 2005:
Associated Press Reports Blood Clot Risk of Ortho Evra
The AP publishes an article stating that the risk of dying or suffering a survivable blood clot while using the Ortho Evra patch is about three times higher than while using birth control pills. The article reports that about a dozen women, most in their late teens and early 20s, died in 2004 from blood clots believed to be related to the birth-control patch Ortho Evra.
• November 10, 2005: FDA Warns Ortho Evra Users of Risks of Blood Clots; New Prescribing Information Announced
The Food and Drug Administration warns users of the Ortho Evra birth control patch that they are being exposed to more hormones, and are therefore at higher risk of blood clots and other serious side effects, than previously disclosed. A strongly worded warning is added to the patch label that says women using the patch will be exposed to about 60 percent more estrogen than those using typical birth control pills.
• September 20, 2006: FDA Again Updates Warning Label; Study Show Two-Fold Increase In Risks of Blood Clots For Ortho Evra Users
The Food and Drug Administration again updates the warning label due to concerns about the increased risk of serious blood clots in Ortho Evra users. The results of two studies are added to the label, one of which shows that patch wearers at twice the risk of birth control pill users to develop serious blood clots. The FDA urges women using the patch to speak with healthcare providers about these risks.
• January 18, 2008:
FDA Makes Third Update to Ortho Evra Warning Label; Additional Study Shows Increase In Risks of Blood Clots For Ortho Evra Users
FDA approves additional changes to the warning label of the Ortho Evra Contraceptive Transdermal Patch to include the results of a new epidemiology study. The study found that users of the Ortho Evra birth control patch ages 15-44, were at a higher risk of developing serious blood clots or venous thromboembolism (VTE) than women using birth control pills. VTE can lead to pulmonary embolism, which is a life-threatening condition.
Additional Lieff Cabraser
Information: Lieff Cabraser Heimann & Bernstein,
LLP, with offices in San Francisco, New York and Nashville, is one of the largest law firms in the United States that
represents only plaintiffs. We have been nationally recognized for our representation
of victims of dangerous and defective medical products. We are representing Ortho Evra birth control patch patients in individual peronal injury lawsuits.
Our clients come from across America, including the states of Alaska, Alabama, Arkansas, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Maryland, Maine, Michigan, Minnesota, Missouri, Montana, North Carolina, North Dakota, Nebraska, New Hampshire, New Jersey, New Mexico, Nevada, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Virginia, Vermont, Washington, Wisconsin, West Virginia and Wyoming. Learn more about our firm.
Disclaimer: The
hiring of legal professionals is an important
decision that should not be based on advertising
alone. Please read our attorney
advertising disclaimer.
Trademark Notice:
Ortho Evra is a trademark of Ortho-McNeil Pharmaceuticals Inc. and is used for
product identification purposes only. The law firm of Lieff Cabraser Heimann & Bernstein,
LLP, is in no way affiliated with Ortho-McNeil Pharmaceuticals Inc. or its subsidiary,
Ortho Women's Health.
